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ABSTRACT: Although genome-wide association studies (GWAS) have identified thousands of trait-associated genetic variants,
there are relatively few findings on the X chromosome. For analysis of low-frequency variants (minor allele frequency <5%),
investigators can use region- or gene-based tests where multiple variants are analyzed jointly to increase power. To date, there
are no gene-based tests designed for association testing of low-frequency variants on the X chromosome. Here we propose
three gene-based tests for the X chromosome: burden, sequence kernel association test (SKAT), and optimal unified SKAT
(SKAT-O). Using simulated case-control and quantitative trait (QT) data, we evaluate the calibration and power of these tests
as a function of (1) male:female sample size ratio; and (2) coding of haploid male genotypes for variants under X-inactivation.
For case-control studies, all three tests are reasonably well-calibrated for all scenarios we evaluated. As expected, power for
gene-based tests depends on the underlying genetic architecture of the genomic region analyzed. Studies with more (haploid)
males are generally less powerful due to decreased number of chromosomes. Power generally is slightly greater when the
coding scheme for male genotypes matches the true underlying model, but the power loss for misspecifying the (generally
unknown) model is small. For QT studies, type I error and power results largely mirror those for binary traits. We demonstrate
the use of these three gene-based tests for X-chromosome association analysis in simulated data and sequencing data from the
Genetics of Type 2 Diabetes (GoT2D) study.
Genet Epidemiol 39:499–508, 2015. © 2015 Wiley Periodicals, Inc.
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Introduction
Genome-wide association studies (GWAS) have identified
thousands of genetic variants associated with hundreds of
diseases and traits [Hindorff et al., 2012]. However, the pro-
portion of associated variants on the X chromosome, relative
to its chromosomal length, lags far behind those on the auto-
somes [Wise et al., 2013]. Analysis of X-chromosome associa-
tion requires proper treatment of diploid female and haploid
male participants. Although we can code female genotypes
under an additive model as the number of minor alleles for
a specific variant: g = {0,1,2}, just as we do for autosomal
variants, for male genotypes, there are two obvious coding
schemes. For a variant under X-inactivation [Lyon, 1961],
where one copy of the female X chromosome is inactivated,
one copy of the male allele is equivalent to two copies of
the female allele, and hence we code haploid male genotypes
as g = {0,2}. For a variant at a locus that does not undergo
X-inactivation, we code male genotypes as g = {0,1}. For
analysis of a mixed sample of males and females, specialized
analytical tools are needed for initial data processing (e.g., es-
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timating allele frequencies and testingHardy-Weinberg equi-
librium) [Purcell et al., 2007], genotype imputation [Howie
et al., 2012; Marchini et al., 2007], and association analysis
[Clayton, 2008; Zheng et al., 2007]. Hence, in many GWAS,
the analysis of the X chromosome has been omitted due to
the additional analysis steps required and/or lack of available
software tools [Wise et al., 2013]. With use of specialized
analytical tools, additional trait-associated variants on the X
chromosome are likely to be identified.
Existing X-chromosome analysis methods focus on single-
marker association analysis. Zheng et al. [2007] proposed
tests comparing differences in allele counts between cases
and controls for males and females jointly, and assume no
X-inactivation (coding male genotypes as g = {0,1}). Clay-
ton [2008] proposed score tests for the additive and domi-
nant genetic models assuming X-inactivation (coding male
genotypes as g = {0,2}). His test assumes equal allele fre-
quencies in males and females; if this assumption is vio-
lated, he recommended stratifying by sex and combining
score statistics across strata. Loley et al. [2011] evaluated the
calibration and power of these tests and showed that no sin-
gle test is uniformly most powerful over all genetic models
and simulation parameters. Loley demonstrated that Clay-
ton’s nonsex-stratified tests can be anti-conservative when
allele frequencies differ between the sexes. Hickey and Bahlo
C© 2015 WILEY PERIODICALS, INC.
[2011] conducted a similar evaluation, and showed that tests
that made use of both male and female data were uniformly
more powerful than tests that only use female data.
Many recent genetic studies use genomeor exome sequenc-
ing [Steinthorsdottir et al., 2014] or specialized genotyping
arrays [Huyghe et al., 2013] to better assay low-frequency ge-
netic variants (minor allele frequency [MAF] < 5%). Single-
marker tests have low power to test for association with low-
frequency variants unless the sample and/or effect size is very
large [Asimit andZeggini, 2010]. In contrast, region- or gene-
based tests in which multiple markers are analyzed jointly
can be more powerful for analyzing low-frequency variants
[Lee et al., 2014]. The calibration and power of gene-based
tests have not been evaluated in the context of analyzing
low-frequency variants on the X chromosome. In this pa-
per, we describe, apply, and evaluate three gene-based tests
for the X chromosome: burden, sequence kernel association
test (SKAT), and optimal unified SKAT (SKAT-O) [Lee et al.,
2012]. Specifically, using simulated binary and quantitative
trait (QT) datasets, we evaluate the calibration and power of
these tests with (1) different male:female ratios in cases and
controls, and (2) different coding of male genotypes.
We find that for case-control studies, all tests are well-
calibrated or very slightly anti-conservative for different
male:female ratios in cases and controls, and different cod-
ing of male genotypes. As expected, power depends on the
underlying genetic architecture of the genomic region ana-
lyzed. Studies with more males than females are typically less
powerful. In most scenarios, power is slightly greater when
we analyze data assuming the true model to code male geno-
types. For QT studies, burden and SKAT are well-calibrated,
while SKAT-O can be slightly anti-conservative, and power
results are similar to those for binary traits. We conclude that
these gene-based tests can be directly applied to the associa-
tion analysis of low-frequency variants for both binary and
QTs.We implemented these tests in the SKATRpackage [Lee,
2014].
Methods
Notation
Consider n individuals sequenced at m variants in a
genomic region of interest. For individual i, let Xi =
(xi1, . . . , xis)′ be the vector of s covariates (including a co-
variate for sex) andGi = (g i1, . . . , g im)′ be the vector of geno-
types. For (diploid) females, let gij = {0,1,2} be the number
of minor alleles for variant j. For (haploid) males, we con-
sider two coding schemes: (1) gij = {0,2} when assuming X-
inactivation in the females and (2) gij = {0,1} when assuming
no X-inactivation. For binary traits, yi = 1 or yi = 0 denotes
a case or control, respectively; for QTs, yi denotes the QT
value. In a combined sample of nm males and nf females (all
unrelated), the maximum-likelihood estimate of the MAF p
of a biallelic variant with alleles A and a is
pˆ =
2naa,f + nAa,f + na,m
2nf + nm
,
where naa,f and nAa,f are the number of females with geno-
types aa and Aa, and na,m is the number of males with the a
allele.
Gene-Based Tests
Forbinary traits,we consider the logistic regressionmodel:
logit(Pr(yi = 1)) = logit(πi) = γ0 + X
′
iγ1 + G
′
iβ, (1)
where γ0 is the intercept, γ1 is the s × 1 vector of regression
coefficients for the covariates, and β = (β1, . . . , βm)′ is the
m × 1 vector of regression coefficients for the genetic vari-
ants. For QTs, the linear regression model is
yi = γ0 + X
′
iγ1 + G
′
iβ + εi, (2)
where εi is the normally distributed error term with mean
zero and variance σ2.
Because there is limited power to test the null hypothesis
that the vector β = 0 for large m, the burden test combines
the genetic effects over the genomic region by assuming βj =
wj βc , given weights wj. Thus, Equations (1) and (2) become
logit(πi) = γ0 + X
′
iγ1 + βc
⎛
⎝
m∑
j =1
wj g ij
⎞
⎠ (3)
yi = γ0 + X
′
iγ1 + βc
⎛
⎝
m∑
j =1
wj g ij
⎞
⎠ + εi (4)
We recommend using MAF-based weights to up-
weight low-frequency variants: wj = Beta(pˆ j , α = 1, β =
25), where weights have beta density function with prespeci-
fied parametersα and β, and pˆ j is the variantMAF [Wu et al.,
2011]. In simulations and real data analysis, we use α = 1 and
β = 25 as suggested byWu et al. [2011]. To test the gene-based
null hypothesis Ho: βc = 0, the burden score statistic is
QB =
⎛
⎝
m∑
j =1
wj Sj
⎞
⎠
2
, (5)
where Sj =
∑n
i=1 (yi – μˆi)g ij is the score statistic for testing
Ho: βj = 0 with only variant j in the regression model, and
μˆi is the estimated mean of yi under Ho. The burden score
statistic is evaluated relative to a scaled χ21 distribution [Wu
et al., 2011].
SKAT assumes theβj’s follow an arbitrary distributionwith
mean zero and variance w2j τ. Testing the null hypothesis Ho:
β = 0 is equivalent to testingHo: τ = 0. The SKAT score statistic
is
QS =
m∑
j =1
w2j S
2
j (6)
and follows a mixture of chi-square distributions [Lee et al.,
2012].
Wu et al. [2011] showed that the power of the burden test
and SKAT depends on the underlying genetic architecture of
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the analyzed genomic region. For example, the burden test is
more powerful when most variants in the region are causal
and have the same direction of effect; in contrast, SKAT is
more powerful when fewer variants are causal and/or have
opposite directions of effect. The combined test of burden test
and SKAT, SKAT-O [Lee et al., 2012] combines the strength
of both tests and is powerful in both scenarios. The SKAT-O
statistic is a weighted average of QB and QS:
Q ρ = ρQB + (1 – ρ)QS , 0 ≤ ρ ≤ 1 (7)
with weight parameter ρ. In practice, ρ is unknown. To es-
timate the optimal ρ, we perform a grid search on 0 = ρ1 <
ρ2 < · · · < ρb = 1 and select ρ such that the Qρ is maximized
(or the corresponding P-value is minimized). We choose to
perform the search on ρ = {0, 0.12, 0.22, 0.32, 0.42, 0.52, 0.5,
1} as suggested by Lee et al. [2012]. Significance is evaluated
analytically by numerical integration [Lee et al., 2012].
For analysis of case-control studies, we examine the effect
of applying the small-sample adjustment described in Lee
et al. [2012].
Numerical Simulations
To generate simulated genomic regions, we used 10,000
haplotypes simulated using the COSI coalescent simulator
[Schaffner et al., 2005], as provided in the SKAT R package.
For each simulated male individual, we randomly selected a
3 Kb region from a single random haplotype. For each sim-
ulated female individual, we selected a 3 Kb region from two
random haplotypes and paired them together. For a simu-
lated sample of 1,000 cases and 1,000 controls under the null
hypothesis, the 3 Kb region has average number of variants
= 36.8 (SD = 6.0), with a median total minor allele count
[MAC] = 2,812 (interquartile range [IQR] = 1,766–4,270).
When considering only variants with MAF < 0.01, the aver-
age number of variants = 28.4 (SD = 5.2), with median total
MAC = 99 (IQR = 79–125).
Type I Error Simulations
For binary traits, we simulated case-control datasets with
Ncases = 1,000 and Nctrls = 1,000 under the logistic regression
model:
logit(πi) = γ0 + γ1X 1i + γ2X 2i + γ3X 3i + β1g i1 + · · · + βtg it
(8)
with one continuous covariate X1i normally distributed with
mean zero and variance one, one binary covariate X2i dis-
tributed Bernoulli with success probability f = 0.5, sex co-
variate X3i, and selected causal variants gi1, . . . , git; under the
null model, we set genetic effects β1 = · · · = βt = 0. The sex
covariate accounts for differences in genotype frequency be-
tween males and females, so that we can avoid inflated type
I error rates as for Clayton’s score test [2008] when allele
frequencies differ between sexes [Loley et al., 2011]. We set
the intercept γ0 so that the disease prevalence is 10%, the co-
variate regression coefficients γ1 = γ2 = 0.5, and the effect for
Table 1. Sample sizes for simulated case-control datasets
Simulation No. of cases males:females No. of controls males:females
A 500:500 500:500
B 900:100 500:500
C 100:900 500:500
Table 2. Sample sizes for simulated quantitative trait datasets
Simulation No. of individuals males:females
D 1,000:1,000
E 200:1,800
F 1,800:200
sex γ3 = 0. We explored a broad range of male:female ratios
in cases and controls by sampling the exact number of males
and females (Table 1) from the simulated cases and controls.
Note that there is an implicit sex-phenotype effect when we
sample unbalanced numbers of males and females in cases
and controls in simulation scenarios B and C (Table 1).
For QTs, we took a similar approach to simulate datasets of
N = 2,000 individuals under the null linear regressionmodel:
yi = γ0 + γ1X 1i + γ2X 2i + γ3X 3i + β1g i1 + · · · + βtg it + εi
(9)
with X1i, X2i, X3i, and gi1, . . . , git as for Equation (8).
We set covariate effect sizes γ1 = γ2 = 0.5, or equivalently,
the proportion of trait variance explained σ2X1 = (γ1)
2 and
σ2X2 = (γ2)
2f (1 – f ); we set the effect of sex γ3 = 0 or 0.5.
The normally distributed residual error had mean zero and
variance = 1 – σ2X1 – σ
2
X2. We sampled the desired number of
males and females (Table 2) from the simulated individuals.
We analyzed each simulated dataset using the six com-
binations of three gene-based tests (Eqs. (5)–(7)) and two
coding schemes for male genotypes. To increase computa-
tional efficiency, we simulated 100,000 independent datasets
per simulation scenario, and resampled the phenotype 1,000
times per independent dataset, resulting in a total of 100
million simulation replicates. We evaluated the robustness of
the resampling approach by comparing results with 1 mil-
lion independent simulated datasets without resampling for
a subset of the simulation scenarios. We estimated type I er-
ror as the proportion of simulation replicates with a P-value
< α = 2.5 × 10–6, corresponding to Bonferroni correction for
association testing of the approximately 20,000 genes in the
human genome.
Power Simulations
Within the 3 Kb region, we selected 10% or 50% of vari-
ants with MAF < 0.03 as causal. Using the same settings as
for the type I error simulations, we simulated case-control
datasets using the logistic regression model (Eq. (8)). We
simulated QT datasets using the linear regression model
(Eq. (9)), assuming the normally distributed residual error εi
had mean zero and variance = 1 – σ2X1 – σ
2
X2 –
∑t
j =1 σ
2
j , where
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Table 3. Type I error rates for burden, SKAT, and SKAT-O tests for simulated binary and quantitative trait studies
Binary traits
Type I error rate (×10–6)
Simulation No. of cases males:females No. of controls males:females Coding for male genotypes Burden SKAT SKAT-O
A 500:500 500:500 No X-inactivation g = {0,1} 2.4 2.6 2.4
X-inactivation g = {0,2} 1.8 1.9 1.6
B 900:100 500:500 No X-inactivation g = {0,1} 3.1 3.9 2.9
X-inactivation g = {0,2} 1.8 2.9 2.1
C 100:900 500:500 No X-inactivation g = {0,1} 3.1 3.4 3.0
X-inactivation g = {0,2} 2.8 5.2 3.7
Quantitative traits
Type I error rate (×10–6)
Simulation No. of individuals males:females Coding for male genotypes Burden SKAT SKAT-O
D 1,000:1,000 No X-inactivation g = {0,1} 2.5 2.1 2.8
X-inactivation g = {0,2} 2.5 2.4 2.8
E 1,800:200 No X-inactivation g = {0,1} 2.7 2.5 3.3
X-inactivation g = {0,2} 2.5 2.4 3.1
F 200:1,800 No X-inactivation g = {0,1} 2.6 2.8 3.4
X-inactivation g = {0,2} 2.7 2.8 3.7
Type I error estimates are based on 108 simulation replicates so that the nominal significance threshold of α = 2.5 × 10–6 corresponds to 250 rejections. Empirical type I error
rates between 2.2 × 10–6 and 2.8 × 10–6 have 95% confidence intervals that include the nominal value.
σ2j = (βj )
22p j (1 – p j ) is the proportion of trait variance ex-
plained by variant j.
We simulated datasets under the alternative hypothesis as-
suming X-inactivation and non-X-inactivation coding for
male genotypes.We assumed genetic effect sizes proportional
to the variantMAF |βj | = c|log10p j |/2, and adjusted the tun-
ing parameter c so that power estimates were not too close to
1 or 0. For binary traits, when 10%of variants were causal, we
set c = log(15), to give an odds ratio of 15 when MAF = 0.01;
when 50% variants were causal, we set c = log(3) or log(5).
For QTs, when 10% of variants were causal, we set c = log(7),
which gave a linear regression coefficient of approximately
1.95 when MAF = 0.01; when 50% of variants were causal,
we set c = log(1.8). We assumed that either all causal variants
were deleterious, or that 50% were deleterious and 50%were
protective. We simulated 1,000 independent replicates per
simulation scenario, and evaluated power as the proportion
of replicates with P-value < 2.5 × 10–6.
Genetics of Type 2 Diabetes (GoT2D) Study
To assess these methods in the context of real data, we an-
alyzed integrated sequencing and genotyping data from the
GoT2D study, which aims to investigate the impact of low-
frequency genetic variation on type 2 diabetes (T2D) risk.
TheGoT2Dstudy sample is composedof 1,326T2Dcases and
1,331 normal glucose tolerant controls from theUnitedKing-
dom (322 cases / 322 controls), Finland (486/517), the Botnia
region of Finland (199/159), Germany (104/101), and Swe-
den (222/227). There are 716 males and 610 females in cases
and 592 males and 739 females in controls. For each sample,
we performed low-pass (5×) whole genome sequencing,
augmented by deep (100×) whole-exome sequencing, and
genotyping of 2.5Msingle nucleotide polymorphisms (SNPs)
using the Illumina HumanOmni2.5 array. To mimic the type
I error and power simulations, we analyzed X-chromosome
data using the six combinations of three gene-based tests and
two coding schemes for male genotypes. For each test, we
adjusted for the effects of sex, the first two genotype-based
principal components (PCs) to control for population strat-
ification [Price et al., 2006], and indicator functions for ob-
served temporal stratification based on sequencing date and
center. To filter out likely neutral variants from the analysis,
we restricted the gene-based analysis to protein-truncating
and missense variants. We used the seqminer [Zhan and Liu,
2013] and SKAT [Lee, 2014] R packages to extract the geno-
types and perform the gene-based analysis, respectively.
Results
Type I Error Rates
For binary traits, the burden, SKAT, and SKAT-O tests are
well-calibrated or slightly anti-conservative (at α = 2.5 ×
10–6) for all scenarios considered (Table 3). For each gene-
based test, we examined type I error rates for two male geno-
type coding schemes: (1) gij = {0,1} and (2) gij = {0,2}; and
datasets with three male:female ratios in cases: (Simulation
A) 500:500, (B) 900:100, and (C) 100:900. For datasets with
male:female ratio = 500:500 in cases (Simulation A), non-X-
inactivation coding is less conservative than X-inactivation
coding for all three tests: burden (non-X-inactivation type
I error rate = 2.4 × 10–6 vs. X-inactivation = 1.8 × 10–6),
SKAT (2.6 × 10–6 vs. 1.9 × 10–6), and SKAT-O (2.4 × 10–6
vs. 1.6 × 10–6). These patterns also hold true for datasets
with male:female ratio = 900:100 in cases (Simulation B). In
comparison, for datasets with male:female ratio = 100:900
in cases (Simulation C), non-X-inactivation coding is less
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Figure 1. Power for gene-based tests in case-control studies assuming all causal variants are deleterious. Causal variants are simulated with
non-X-inactivation coding of male genotypes gij = {0,1}. Within each simulated 3 Kb genomic region, (A–C) 10% or (D–F) 50% of variants with MAF
< 0.03 are selected as causal. The effect size for causal variants is given by |β j | = c |log10 p j |/2, and is proportional to MAF (pj) and scaled by
tuning parameter (A–C) c = log(15) and (D–F) c = log(3); all causal variants are simulated as deleterious. Simulated cases have (A, D) 500:500, (B, E)
900:100, and (C, F) 100:900 males and females, respectively. All simulated controls have 500 males and 500 females. Power estimates (at α = 2.5 ×
10−6) are based on 1,000 simulation replicates; vertical bars denote the exact binomial 95% confidence intervals.
conservative for burden, butmore conservative for SKAT and
SKAT-O. These results are generalizable to other male:female
sample sizes and depend only on the male:female ratio in
cases and controls (supplementary Fig. S1).
We examined the impact of the implicit nonzero sex-
phenotype effect on test calibration by sampling unbalanced
numbers of males and females in cases and controls (Simu-
lations B and C; Table 1). Tests are similarly calibrated with
or without the sex-phenotype effect (Table 3). We also exam-
ined the effect of applying the small-sample adjustment [Lee
et al., 2012] to the three gene-based tests; type I error rates are
generally slightly anti-conservative after applying the small-
sample adjustment (supplementary Fig. S1), but the patterns
of type I error rates between male genotype coding schemes
and male:female ratios are identical to those without small-
sample adjustment. Finally, we demonstrated the accuracy of
our computationally efficient resampling approach by com-
paring type I error rates with resampling to those without
resampling (106 independent replicates; α = 5 × 10–4); type I
error rates are comparable with (supplementary Fig. S2A–C)
and without resampling (supplementary Fig. S2D–F).
For QTs, the burden and SKAT tests are well-calibrated and
SKAT-Ocanbevery slightly anti-conservative across the three
simulated datasets with male:female ratios of 1,000:1,000;
1,800:200; and 200:1,800 (Table 3). Type I error rates are
nearly identical between the two male coding schemes. Tests
are similarly well-calibrated with or without the inclusion of
a nonzero sex-phenotype effect (supplementary Table S1).
Power
We examined power for four combinations of proportion
of causal variants in a region (10%or 50%) and causal variant
direction of effect (all deleterious, or 50% deleterious and
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Figure 2. Power for gene-based tests in case-control studies assuming causal variants are 50% deleterious and 50% protective. Causal variants
are simulated with non-X-inactivation coding of male genotypes gij = {0,1}. Within each simulated 3 Kb genomic region, (A–C) 10% or (D–F) 50%
of variants with MAF < 0.03 are selected as causal. The effect size for causal variants is given by |β j | = c |log10 p j |/2, and is proportional to MAF
(pj) and scaled by tuning parameter (A–C) c = log(15) and (D–F) c = log(5); causal variants are simulated as 50% deleterious and 50% protective.
Simulated cases have (A, D) 500:500, (B, E) 900:100, and (C, F) 100:900 males and females, respectively. All simulated controls have 500 males and
500 females. Power estimates (at α = 2.5 × 10−6) are based on 1,000 simulation replicates; vertical bars denote the exact binomial 95% confidence
intervals.
50% protective). For binary traits, power results (Figs. 1 and
2) reflect the previously described relative power of gene-
based tests for different underlying genetic architectures [Lee
et al., 2012]. For example, the burden test is more powerful
when 50% of low-frequency variants are causal and have the
same direction of effect (Fig. 1D–F). SKAT is more powerful
when 10%of low-frequency variants are causal with the same
or opposite direction of effect (Fig. 1A–C), or when 50%
of causal variants have opposite direction of effect (Fig. 2).
SKAT-O is generally robust and powerful across all scenarios
tested.Despite the slightly anti-conservative type I error rates,
the small-sample adjusted and nonadjusted power estimates
are comparable (data not shown).
Next, we investigated the effect of simulating causal vari-
ants with (male genotype coding gij = {0,2}) and without (gij
= {0,1}) X-inactivation. The two coding schemes for male
genotypes have only a small effect on power. When simulat-
ing variants assuming no X-inactivation, non-X-inactivation
coding (gij = {0,1}) is slightly more powerful in all scenarios
(Figs. 1 and 2). However, when simulating variants assuming
X-inactivation, X-inactivation coding (gij = {0,2}) is slightly
more powerful in nearly all scenarios (supplementary Figs.
S3 and S4).However, the power loss formisspecifying the un-
knownmodel is small. For example, in simulations assuming
non-X-inactivation coding, the largest power loss for mis-
specifying the coding scheme is 7.7% (32.7% vs. 25.0%) for
SKAT (Fig. 1E), and the average absolute difference is 2.8%.
Power is generally lower for studies with more males than
females, due to decreased effective sample size (e.g., number
of chromosomes). For example, for the burden test with non-
X-inactivation coding (gij = {0,1}), studies with 900males:100
females in cases is less powerful than with 500 males:
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Figure 3. Power for gene-based tests in QT studies assuming all causal variants are deleterious. Causal variants are simulated with non-X-
inactivation coding of male genotypes gij = {0,1}. Within each simulated 3 Kb genomic region, (A–C) 10% or (D–F) 50% of variants with MAF < 0.03
are selected as causal. The effect size for causal variants is given by |β j | = c |log10 p j |/2, and is proportional to MAF (pj) and scaled by tuning
parameter (A–C) c = log(7) and (D–F) c = log(1.8); all causal variants are simulated as deleterious. Simulated datasets have (A, D) 1,000:1,000, (B,
E) 1,800:200, and (C, F) 200:1,800 males and females, respectively. Power estimates (at α = 2.5 × 10−6) are based on 1,000 simulation replicates;
vertical bars denote the exact binomial 95% confidence intervals.
500 females (44.6% vs. 65.4%; Fig. 1D and 1E). Finally, for
QTs, power comparisons are very similar to those for binary
traits (Figs. 3 and 4).
Analysis of GoT2D X-Chromosome Data
To examine the effect of different coding schemes for male
genotypes, we performed gene-based association testing for
505 X-chromosome genes with T2D risk using low-pass se-
quencing data from 1,326 T2D cases and 1,331 healthy con-
trols from the GoT2D study. Within each gene region, we
restricted the variants to those predicted to be protein trun-
cating or missense mutations. Gene regions had an average
number of variants = 6.1 (SD = 5.5), and amedian total MAC
= 9 (IQR = 4–20). We analyzed the data using six combina-
tions of three gene-based tests and twomale genotype coding
schemes, adjusting for the effects of sex and the first two PCs
to account for population stratification.
Scatterplots and quantile-quantile plots show that the
association analysis P-values are concordant between X-
inactivation and non-X-inactivation coding for all three
tests (Fig. 5A–F). The differences in P-value between cod-
ing schemes are generally small (Fig. 5G–I). For example,
for the burden test, 68.5% (346/505 genes) of the analysis
P-values have an absolute difference of 0.1 log10 units or less;
99.4% (502/505) of P-values are within 0.5 log10 units.
Discussion
We examined the calibration and power of the burden,
SKAT, and SKAT-O gene-based association tests for analyz-
ing the X chromosome in simulated binary and QT data.
For binary traits, all tests are well-calibrated or slightly anti-
conservative for all simulation scenarios. Power differences
reflected the previously described strengths and weaknesses
of each test for analyzing regions with differing underly-
ing genetic architectures. Power is usually slightly increased
when we code male genotypes with the coding scheme that
matches the underlying genetic model (e.g., with or without
X-inactivation), but power loss is modest when we misspec-
ify the (unknown) coding scheme. Studies with more male
samples typically have lower power. For QTs, the burden and
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Figure 4. Power for gene-based tests in QT studies assuming causal variants are 50% deleterious and 50% protective. Causal variants are
simulated with non-X-inactivation coding of male genotypes gij = {0,1}. Within each simulated 3 Kb genomic region, (A–C) 10% or (D–F) 50% of
variants with MAF < 0.03 are selected as causal. The effect size for causal variants is given by |β j | = c |log10 p j |/2, and is proportional to MAF
(pj) and scaled by tuning parameter (A–C) c = log(7) and (D–F) c = log(1.8); causal variants are simulated as 50% deleterious and 50% protective.
Simulated datasets have (A, D) 1,000:1,000, (B, E) 1,800:200, and (C, F) 200:1,800 males and females, respectively. Power estimates (at α = 2.5× 10−6)
are based on 1,000 simulation replicates; vertical bars denote the exact binomial 95% confidence intervals.
SKAT tests are well-calibrated, and SKAT-O is very slightly
anti-conservative; power resultsmirror those forbinary traits.
In practice, investigators will need to use external biologi-
cal information to select the preferred male coding scheme.
For example, we recommend using the non-X-inactivation
coding scheme for known pseudoautosomal regions. In the
absence of external information, we suggest using the X-
inactivation coding because a higher proportion of X-linked
genes do undergo X-inactivation. It is known that only 15%
of X-linked genes escape inactivation to some degree [Carrel
and Willard, 2005]. We have demonstrated that misspecify-
ing the coding scheme leads to only a small loss in power.
In the GoT2D study, we also demonstrated that using either
coding scheme produces similar results.
Although we only presented calibration and power results
for a specific set of simulation settings, we performed a vari-
ety of simulations with other covariate settings, case:control
ratios, and prevalence rates to demonstrate that our results
are generalizable (data not shown). We also considered the
effect on calibration of allele frequency differences between
males and females. To introduce large differences in allele
frequency between sexes, we sampled male genotypes from a
set of simulated haplotypes mimicking European American
ancestry, and female genotypes from haplotypes mimick-
ing African American ancestry. The gene-based tests remain
well-calibrated despite the allele frequency differences (sup-
plementary Table S2).
We estimated nominal power as the proportion of simu-
lation replicates (under the alternative hypothesis) with P-
values < 2.5 × 10–6. We estimated empirical power as the
proportion of simulated datasets with P-values less than the
estimated empirical threshold: the αth quantile of the 108
P-values for the simulated samples under the null hypoth-
esis. Overall, power using nominal or empirical thresholds
yield near-identical power because tests are relatively well-
calibrated across all scenarios, and the empirical thresholds
(range = 1 × 10–6–3.5 × 10–6) are very similar to the nom-
inal significance threshold. The greatest difference between
nominal and empirical power is for a study with 100 males
and 900 females in cases, and 500 males and 500 females
in controls, where 50% of low-frequency variants are causal
and have the same direction of effect. For the SKAT test using
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X-inactivation coding (gij = {0,2}), nominal power = 41.7%vs.
empirical power = 40.1%. We decided to present our power
results assuming nominal thresholds, because this is how
analysis actually will be done.
We did not evaluate the calibration and power for other
gene-based association methods, such as the WST [Madsen
and Browning, 2009], C-alpha [Neale et al., 2011], and SSU
[Pan, 2009] tests. However, our burden test is equivalent to
the WST, and SKAT includes the C-alpha and SSU tests as a
special case, indicating that our results would likely extend to
these gene-based tests. We only evaluate test calibration and
power assuming an additive genetic model. For gene-based
tests, we are primarily interested in testing the (joint) effect
of rare variants. Because minor allele homozygotes are rare,
we expect the dominant genetic model to have near identical
calibration and power to the additivemodel, and the recessive
model to have very low power. We only explored the effect of
randomX-inactivation, where50% of the cells have one fe-
male allele inactivated and the remaining50% of the other.
We did not examine the possibility of nonrandom or skewed
X-inactivation [Amos-Landgraf et al., 2006], where >75% of
cells have one allele inactivated. Although a unified approach
to account for both random and nonrandom X-inactivation
may be more robust and powerful, as demonstrated byWang
et al. [2014] for single-marker association testing, we specu-
late that misspecifying the model for the burden, SKAT, and
SKAT-O gene-based tests will only result in a small power
loss.
In conclusion,wegeneralized theburden, SKAT, andSKAT-
O tests to analyzeX-chromosomevariants, anddemonstrated
that these tests are generallywell-calibrated andpowerful for a
wide range of simulation scenarios. These tests can be directly
applied to the association analysis of less common variants
on the X chromosome.
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